The research programme of the Wolfson Drug Discovery Unit, directed by Professor Sir Mark B Pepys FRS, is highly collaborative and focused on development of effective therapies for treatment of amyloidosis and other major diseases associated with local amyloid deposition, and cardiovascular disease.

My research efforts are focused primarily on: (1) Characterisation of cellular mechanisms responsible for removal of amyloid in tissues of patients with systemic amyloidosis, including the propensity of monocyte-derived macrophages to form multinucleated giant cells (MGCs); (2) Evaluation of ex vivo amyloid fibrils, amyloid-like fibrils produced in vitro, and anti-amyloid fibril antibodies for functional and structural studies; (3) Thermodynamic characterisation of complexes formed between novel compounds and C-reactive protein (CRP), serum amyloid P component (SAP) or transthyretin (TTR), by isothermal titration and/or differential scanning calorimetry, for drug development studies.